SBI Securities’s Silexion Therapeutics SLXN Stock Holding History

SBI Securities’s Portfolio SLXN Stock Details SLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4	Buy	14 +12	+600%	+$15	﹤0.01%	4068
2026 Q2	$5	Hold	2	–	–	﹤0.01%	3997
2026 Q1	$26	Sell	2 -104	-98%	-$1.82K	﹤0.01%	3717
2025 Q4	$2.04K	Hold	106	–	–	﹤0.01%	2371
2025 Q3	$3.6K	Sell	106 -3	-3%	-$249	﹤0.01%	2188
2025 Q2	$13.3K	Hold	109	–	–	﹤0.01%	1581
2025 Q1	$18.1K	Buy	+109	New	+$21.6K	﹤0.01%	1373

SBI Securities's SLXN Position: Q3 2026 in Review

SBI Securities increased its Silexion Therapeutics (SLXN) stake by 600% in Q3 2026, buying an estimated $15 and bringing the position to 14 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #4068.

SBI Securities first reported a position in SLXN in Q1 2025 and has held it in 7 quarters since. The position peaked at $18.1K in Q1 2025. 1 fund tracked by Wall St. Rank holds SLXN as of Q3 2026.

SBI Securities held 14 shares of Silexion Therapeutics worth $4 as of Q3 2026.
SBI Securities bought 12 Silexion Therapeutics shares in Q3 2026, an estimated $15.
Silexion Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #4068 holding.
SBI Securities first reported a position in Silexion Therapeutics in Q1 2025 and has held it in 7 quarters since.
SBI Securities's Silexion Therapeutics position peaked at $18.1K in Q1 2025.
1 fund tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.